Last reviewed · How we verify
NCT03626584
PET/MR Imaging In Patients With Cardiac Amyloidosis
trial testing 18F-NaF PET in Cardiac Amyloidosis in 33 participants. Completed in 6 February 2020.
6 February 2020
Quick facts
| Lead sponsor | University of Edinburgh |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 25 August 2017 |
| Primary completion | 6 February 2020 |
| Estimated completion | 6 February 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 18F-NaF PET
Conditions studied
- Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →
Sponsor
University of Edinburgh
Who can join
50 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PET scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. It involves injecting a radioactive tracer which highlights abnormal areas. It has recently been combined with CT (computed tomography) and MRI (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. Cardiac amyloidosis, a condition which causes thickening of heart muscle due to abnormal protein deposits, is of particular interest. There are different forms of this condition and at present samples of tissue need to be taken and analysed in order to assess these accurately, which carries risks. The study makes use of hybrid PET/MR scanning using a designated scanner which enables PET scanning combined with MRI scanning. The investigators will use a PET tracer which is widely used in cardiac imaging as it is hoped this will enable characterisation of abnormal areas within the heart in this condition in a way which hasn't been done before. All participants will undergo PET scanning, where a radioactive tracer is injected into a vein before the scan. The radioactive substance only lasts for a short time and is safe, passed out of the body in urine. If successful, this imaging method will enable us to detect differences between different forms of cardiac amyloidosis in a non-invasive way, improving the diagnostic capabilities in this condition.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Non-invasive imaging of the coronary arteries.
Adamson PD, Newby DE. · · 2019 · cited 29× · PMID 30388261 · DOI 10.1093/eurheartj/ehy670 -
18F-fluoride PET/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls.
Andrews JPM, Trivieri MG, Everett R, Spath N, et al · · 2022 · cited 15× · PMID 33000405 · DOI 10.1007/s12350-020-02356-1
Verify or expand the search:
- PubMed search for NCT03626584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 18F-NaF PET
Trials testing the same drug.
- NCT03689946 — Effect of Evolocumab on Coronary Atherosclerosis · Phase 3 · completed
Other recruiting trials for Cardiac Amyloidosis
Currently open trials in the same condition.
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06788535 — Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis · Phase 3 · active not recruiting
- NCT06458374 — ATTR Cardiac Amyloidosis in a Selected Population · recruiting
- NCT06427304 — Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure · recruiting
- NCT06907836 — Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine · recruiting
Other University of Edinburgh trials
Trials by the same sponsor.
- NCT07341126 — Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal · not yet recruiting
- NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
- NCT07430540 — Optimising Colorectal Cancer Patient Pathways · NA · not yet recruiting
- NCT07430527 — Secondary Care Colorectal Cancer Pathway Review · not yet recruiting
- NCT07436026 — Latin America Network for Primary Palliative Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03626584 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Edinburgh
- Last refreshed: 17 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03626584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing